{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:14:15Z","timestamp":1789193655411,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.apsb.2024.03.021","type":"journal-article","created":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T17:10:23Z","timestamp":1711559423000},"page":"3110-3124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Design and optimization of piperidine-substituted thiophene[3,2-d]pyrimidine-based HIV-1 NNRTIs with improved drug resistance and pharmacokinetic profiles"],"prefix":"10.1016","volume":"14","author":[{"given":"Yanying","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongling","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongji","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2985-8890","authenticated-orcid":false,"given":"Erik","family":"De Clercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Pannecouque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwei","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4120-6937","authenticated-orcid":false,"given":"Xinyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2024.03.021_bib1","unstructured":"HIV data and statistics. https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/strategic-information\/hiv-dataand-statistics."},{"key":"10.1016\/j.apsb.2024.03.021_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp1916753","article-title":"Four decades of HIV\/AIDS\u2015much accomplished, much to do","volume":"383","author":"Fauci","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2024.03.021_bib3","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.apsb.2021.11.009","article-title":"Approved HIV reverse transcriptase inhibitors in the past decade","volume":"12","author":"Li","year":"2022","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2024.03.021_bib4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.24875\/AIDSRev.21000068","article-title":"Research progress on HIV-1 immune escape mechanisms","volume":"24","author":"Meng","year":"2022","journal-title":"AIDS Rev"},{"key":"10.1016\/j.apsb.2024.03.021_bib5","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/med.21544","article-title":"Challenges and approaches in the discovery of human immunodeficiency virus type-1 non-nucleoside reverse transcriptase inhibitors","volume":"39","author":"Battini","year":"2019","journal-title":"Med Res Rev"},{"key":"10.1016\/j.apsb.2024.03.021_bib6","doi-asserted-by":"crossref","first-page":"9743","DOI":"10.1021\/ja4018418","article-title":"Thermodynamics of HIV-1 reverse transcriptase in action elucidates the mechanism of action of non-nucleoside inhibitors","volume":"135","author":"Bec","year":"2013","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2024.03.021_bib7","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1021\/acs.jmedchem.8b00843","article-title":"The journey of HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) from lab to clinic","volume":"62","author":"Namasivayam","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.021_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2024.101053","article-title":"Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges","volume":"73","author":"Du","year":"2024","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.apsb.2024.03.021_bib9","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/j.cclet.2020.03.028","article-title":"New techniques and strategies in drug discovery","volume":"31","author":"Du","year":"2020","journal-title":"Chin Chem Lett"},{"key":"10.1016\/j.apsb.2024.03.021_bib10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/QAI.0b013e3182515730","article-title":"Low-frequency nevirapine resistance at multiple\u00a0sites may predict treatment failure in infants on nevirapine-based treatment","volume":"60","author":"Lehman","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.apsb.2024.03.021_bib11","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1021\/acs.chemrev.0c00967","article-title":"Avoiding drug resistance in HIV reverse transcriptase","volume":"121","author":"Cilento","year":"2021","journal-title":"Chem Rev"},{"key":"10.1016\/j.apsb.2024.03.021_bib12","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMp1710608","article-title":"HIV drug resistance\u2015an emerging threat to epidemic control","volume":"377","author":"Beyrer","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2024.03.021_bib13","doi-asserted-by":"crossref","first-page":"11300","DOI":"10.1128\/JVI.05584-11","article-title":"Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I\/V mutations","volume":"85","author":"Xu","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2024.03.021_bib14","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/AAC.04201-14","article-title":"In\u00a0vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways","volume":"59","author":"Feng","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2024.03.021_bib15","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/17425255.2019.1673367","article-title":"Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment","volume":"15","author":"Wang","year":"2019","journal-title":"Expert Opin Drug Met"},{"key":"10.1016\/j.apsb.2024.03.021_bib16","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1021\/acs.jmedchem.1c01758","article-title":"Contemporary medicinal chemistry strategies for the discovery and development of novel HIV-1 non-nucleoside reverse transcriptase inhibitors","volume":"65","author":"Wang","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.021_bib17","doi-asserted-by":"crossref","first-page":"7991","DOI":"10.1021\/acs.jmedchem.6b00738","article-title":"Design, synthesis, and evaluation of thiophene[3,2-d]pyrimidine derivatives as HIV-1 non-nucleoside reverse transcriptase inhibitors with significantly improved drug resistance profiles","volume":"59","author":"Kang","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.021_bib18","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1021\/acs.jmedchem.7b00332","article-title":"Structure-based optimization of thiophene[3,2-d]pyrimidine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with improved potency against resistance-associated variants","volume":"60","author":"Kang","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.021_bib19","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.36340","article-title":"Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-d]pyrimidine non-nucleoside inhibitors","volume":"7","author":"Yang","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.apsb.2024.03.021_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jevs.2020.103339","article-title":"Adverse effect of antibiotics administration on horse health: an overview","volume":"97","author":"Khusro","year":"2021","journal-title":"J Equine Vet Sci"},{"key":"10.1016\/j.apsb.2024.03.021_bib21","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0968-0896(02)00514-X","article-title":"Water soluble prodrugs of the antitumor agent 3-[(3-amino-4-methoxy)phenyl]-2-(3,4,5-trimethoxyphenyl)cyclopent-2-ene-1-one","volume":"11","author":"Nam","year":"2003","journal-title":"Bioorgan Med Chem"},{"key":"10.1016\/j.apsb.2024.03.021_bib22","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0928-0987(03)00044-7","article-title":"Anandamide prodrugs. 1. water-soluble phosphate esters of arachidonylethanolamide and R-methanandamide","volume":"19","author":"Juntunen","year":"2003","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.apsb.2024.03.021_bib23","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1021\/jm030868a","article-title":"Synthesis, in\u00a0vitro evaluation, and antileishmanial activity of water-soluble prodrugs of buparvaquone","volume":"47","author":"M\u00e4ntyl\u00e4","year":"2004","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.021_bib24","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nprot.2007.517","article-title":"Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later","volume":"3","author":"Pannecouque","year":"2008","journal-title":"Nat Protoc"},{"key":"10.1016\/j.apsb.2024.03.021_bib25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0166-0934(93)90054-U","article-title":"Poly A-linked colorimetric microtiter plate assay for HIV reverse transcriptase","volume":"44","author":"Suzuki","year":"1993","journal-title":"J Virol Methods"},{"key":"10.1016\/j.apsb.2024.03.021_bib26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1208\/s12249-017-0808-z","article-title":"In situ salification in polar solvents: a paradigm for enabling drug delivery of weakly ionic drugs as amorphous solid dispersion","volume":"19","author":"Nair","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.apsb.2024.03.021_bib27","doi-asserted-by":"crossref","first-page":"4837","DOI":"10.1021\/acs.jmedchem.0c00117","article-title":"Structure-based bioisosterism yields HIV-1 NNRTIs with improved drug-resistance profiles and favorable pharmacokinetic properties","volume":"63","author":"Kang","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2024.03.021_bib28","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1016\/j.apsb.2023.01.003","article-title":"Discovery of novel sulfonamide substituted indolylarylsulfones as potent HIV-1 inhibitors with better safety profiles","volume":"13","author":"Gao","year":"2023","journal-title":"Acta Pharm Sin B"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524001023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383524001023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T03:10:45Z","timestamp":1720581045000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383524001023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2211383524001023"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2024.03.021","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design and optimization of piperidine-substituted thiophene[3,2-d]pyrimidine-based HIV-1 NNRTIs with improved drug resistance and pharmacokinetic profiles","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2024.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}